VitaNova Life Sciences Corporation Financials
This page shows VitaNova Life Sciences Corporation (VNOV) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
VitaNova Life Sciences Corporation has an operating margin of 45.4%, meaning the company retains $45 of operating profit per $100 of revenue. This strong profitability earns a score of 100/100, reflecting efficient cost management and pricing power. This is up from 36.0% the prior year.
VitaNova Life Sciences Corporation's revenue surged 366.5% year-over-year to $2.7M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
VitaNova Life Sciences Corporation carries a low D/E ratio of 0.20, meaning only $0.20 of total debt for every $1 of shareholders' equity. This conservative leverage earns a score of 98/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 5.90, VitaNova Life Sciences Corporation holds $5.90 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
VitaNova Life Sciences Corporation earns a strong 45.7% return on equity (ROE), meaning it generates $46 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 100/100. This is up from 14.1% the prior year.
VitaNova Life Sciences Corporation scores 68.06, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($40.3M) relative to total liabilities ($380K). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
VitaNova Life Sciences Corporation passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, VitaNova Life Sciences Corporation generates $0.23 in operating cash flow ($193K OCF vs $851K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
VitaNova Life Sciences Corporation earns $268.2 in operating income for every $1 of interest expense ($1.2M vs $5K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
VitaNova Life Sciences Corporation generated $2.7M in revenue in fiscal year 2025. This represents an increase of 366.5% from the prior year.
VitaNova Life Sciences Corporation's EBITDA was -$72K in fiscal year 2019, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 47.6% from the prior year.
VitaNova Life Sciences Corporation reported $851K in net income in fiscal year 2025. This represents an increase of 503.9% from the prior year.
VitaNova Life Sciences Corporation earned $0.03 per diluted share (EPS) in fiscal year 2025. This represents an increase of 200.0% from the prior year.
Cash & Balance Sheet
VitaNova Life Sciences Corporation held $1.0M in cash against $0 in long-term debt as of fiscal year 2025.
VitaNova Life Sciences Corporation had 25M shares outstanding in fiscal year 2025. This represents an increase of 0.0% from the prior year.
Margins & Returns
VitaNova Life Sciences Corporation's gross margin was 59.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 7.0 percentage points from the prior year.
VitaNova Life Sciences Corporation's operating margin was 45.4% in fiscal year 2025, reflecting core business profitability. This is up 9.4 percentage points from the prior year.
VitaNova Life Sciences Corporation's net profit margin was 32.0% in fiscal year 2025, showing the share of revenue converted to profit. This is up 7.3 percentage points from the prior year.
VitaNova Life Sciences Corporation's ROE was 45.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 31.6 percentage points from the prior year.
Capital Allocation
VNOV Income Statement
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $710K0.0% | $710K+66.1% | $427K+311.1% | $104K-94.7% | $2.0M+533.5% | $308K+5.5% | $292K+169.3% | $108K |
| Cost of Revenue | $393K0.0% | $393K+136.5% | $166K+373.6% | $35K-95.6% | $796K+568.7% | $119K-12.7% | $136K+286.0% | $35K |
| Gross Profit | $316K0.0% | $316K+21.3% | $261K+279.2% | $69K-94.1% | $1.2M+511.4% | $189K+21.5% | $156K+113.0% | $73K |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $220K0.0% | $220K+83.9% | $119K+80.2% | $66K+122.6% | $30K-2.9% | $31K-23.5% | $40K-30.3% | $58K |
| Operating Income | $47K0.0% | $47K-52.9% | $99K+405.7% | -$32K-103.0% | $1.1M+894.0% | $109K+73.9% | $63K+237.8% | -$45K |
| Interest Expense | $3K | $0 | $0 | N/A | N/A | $813-61.7% | $2K | N/A |
| Income Tax | $91K0.0% | $91K+43.5% | $63K+358.0% | $14K-95.1% | $280K+694.7% | $35K+25.4% | $28K+187.1% | $10K |
| Net Income | -$44K0.0% | -$44K-223.9% | $36K+177.3% | -$46K-105.8% | $800K+996.7% | $73K+123.5% | $33K+159.1% | -$55K |
| EPS (Diluted) | -$0.010.0% | -$0.01 | $0.00 | $0.00 | N/A | $0.01 | $0.00 | $0.00 |
VNOV Balance Sheet
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.3M0.0% | $2.3M-1.0% | $2.3M+4.2% | $2.2M-0.6% | $2.3M+70.8% | $1.3M+5.0% | $1.3M+4.8% | $1.2M |
| Current Assets | $2.3M0.0% | $2.3M-1.0% | $2.3M+4.2% | $2.2M-0.6% | $2.3M+70.8% | $1.3M+5.0% | $1.3M+4.8% | $1.2M |
| Cash & Equivalents | $783K-33.0% | $1.2M-7.2% | $1.3M+20.3% | $1.0M+33.7% | $783K+93.2% | $405K+81.9% | $223K+57.3% | $142K |
| Inventory | $130K0.0% | $130K+1057.7% | $11K+23.4% | $9K-79.4% | $44K-76.3% | $187K-38.4% | $303K+42.0% | $213K |
| Accounts Receivable | $1.0M0.0% | $1.0M+13.8% | $883K-13.0% | $1.0M-19.9% | $1.3M+2245.4% | $54K-6.4% | $58K | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $458K0.0% | $458K+4.5% | $438K+15.3% | $380K+9.3% | $348K+63.3% | $213K-5.0% | $224K+12.3% | $199K |
| Current Liabilities | $458K0.0% | $458K+4.5% | $438K+15.3% | $380K+9.3% | $348K+63.3% | $213K-5.0% | $224K+12.3% | $199K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $1.9M0.0% | $1.9M-2.3% | $1.9M+1.9% | $1.9M-2.4% | $1.9M+72.2% | $1.1M+7.1% | $1.0M+3.3% | $1.0M |
| Retained Earnings | $813K0.0% | $813K-5.2% | $857K+4.4% | $821K-5.3% | $868K+1188.0% | $67K+1301.1% | -$6K+85.3% | -$38K |
VNOV Cash Flow Statement
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $386K+527.2% | -$90K-142.5% | $213K-19.4% | $264K-44.9% | $479K+129.4% | $209K+2284.5% | $9K+101.7% | -$504K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $99K | $0 | $0 | $0+100.0% | -$102K-283.0% | -$27K-136.6% | $72K+37.6% | $53K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
VNOV Financial Ratios
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 44.6%0.0pp | 44.6%-16.5pp | 61.1%-5.1pp | 66.2%+6.9pp | 59.3%-2.1pp | 61.4%+8.1pp | 53.3%-14.1pp | 67.5% |
| Operating Margin | 6.6%0.0pp | 6.6%-16.6pp | 23.2%+54.4pp | -31.2%-86.6pp | 55.4%+20.1pp | 35.3%+13.9pp | 21.4%+63.3pp | -41.9% |
| Net Margin | -6.3%0.0pp | -6.3%-14.6pp | 8.4%+52.9pp | -44.6%-85.5pp | 41.0%+17.3pp | 23.7%+12.5pp | 11.2%+62.1pp | -50.9% |
| Return on Equity | -2.4%0.0pp | -2.4%-4.3pp | 1.9%+4.4pp | -2.5%-44.4pp | 41.9%+35.4pp | 6.6%+3.4pp | 3.1%+8.7pp | -5.5% |
| Return on Assets | -1.9%0.0pp | -1.9%-3.4pp | 1.5%+3.6pp | -2.1%-37.5pp | 35.5%+29.9pp | 5.5%+2.9pp | 2.6%+7.2pp | -4.6% |
| Current Ratio | 5.050.0 | 5.05-0.3 | 5.33-0.6 | 5.90-0.6 | 6.49+0.3 | 6.21+0.6 | 5.62-0.4 | 6.02 |
| Debt-to-Equity | 0.250.0 | 0.25+0.0 | 0.23+0.0 | 0.20+0.0 | 0.180.0 | 0.19-0.0 | 0.22+0.0 | 0.20 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Frequently Asked Questions
What is VitaNova Life Sciences Corporation's annual revenue?
VitaNova Life Sciences Corporation (VNOV) reported $2.7M in total revenue for fiscal year 2025. This represents a 366.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is VitaNova Life Sciences Corporation's revenue growing?
VitaNova Life Sciences Corporation (VNOV) revenue grew by 366.5% year-over-year, from $571K to $2.7M in fiscal year 2025.
Is VitaNova Life Sciences Corporation profitable?
Yes, VitaNova Life Sciences Corporation (VNOV) reported a net income of $851K in fiscal year 2025, with a net profit margin of 32.0%.
What is VitaNova Life Sciences Corporation's earnings per share (EPS)?
VitaNova Life Sciences Corporation (VNOV) reported diluted earnings per share of $0.03 for fiscal year 2025. This represents a 200.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is VitaNova Life Sciences Corporation's gross margin?
VitaNova Life Sciences Corporation (VNOV) had a gross margin of 59.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is VitaNova Life Sciences Corporation's operating margin?
VitaNova Life Sciences Corporation (VNOV) had an operating margin of 45.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is VitaNova Life Sciences Corporation's net profit margin?
VitaNova Life Sciences Corporation (VNOV) had a net profit margin of 32.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is VitaNova Life Sciences Corporation's return on equity (ROE)?
VitaNova Life Sciences Corporation (VNOV) has a return on equity of 45.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is VitaNova Life Sciences Corporation's operating cash flow?
VitaNova Life Sciences Corporation (VNOV) generated $193K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are VitaNova Life Sciences Corporation's total assets?
VitaNova Life Sciences Corporation (VNOV) had $2.2M in total assets as of fiscal year 2025, including both current and long-term assets.
How many shares does VitaNova Life Sciences Corporation have outstanding?
VitaNova Life Sciences Corporation (VNOV) had 25M shares outstanding as of fiscal year 2025.
What is VitaNova Life Sciences Corporation's current ratio?
VitaNova Life Sciences Corporation (VNOV) had a current ratio of 5.90 as of fiscal year 2025, which is generally considered healthy.
What is VitaNova Life Sciences Corporation's debt-to-equity ratio?
VitaNova Life Sciences Corporation (VNOV) had a debt-to-equity ratio of 0.20 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is VitaNova Life Sciences Corporation's return on assets (ROA)?
VitaNova Life Sciences Corporation (VNOV) had a return on assets of 37.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is VitaNova Life Sciences Corporation's Altman Z-Score?
VitaNova Life Sciences Corporation (VNOV) has an Altman Z-Score of 68.06, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is VitaNova Life Sciences Corporation's Piotroski F-Score?
VitaNova Life Sciences Corporation (VNOV) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are VitaNova Life Sciences Corporation's earnings high quality?
VitaNova Life Sciences Corporation (VNOV) has an earnings quality ratio of 0.23x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can VitaNova Life Sciences Corporation cover its interest payments?
VitaNova Life Sciences Corporation (VNOV) has an interest coverage ratio of 268.2x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is VitaNova Life Sciences Corporation?
VitaNova Life Sciences Corporation (VNOV) scores 100 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.